I don’t think so because Generex hasn’t even filed a registration statement yet with the SEC. Let’s think of the wider picture that while Joe and Generex are building a unique healthcare holding company, WITH their own MSO network, they currently are an OTC trading biotech that is actually rolling out their first commercial product Excellagen. Typically, an OTC biotech talks endlessly about commercialization but never sees that fruit to bear. Instead, most (by far) of funds raised goes to salaries. Joe and the main group of indiders aren’t getting a salary and they are priming commercialization. They’ve set up a sales force. I’d guess the nominal amount of capital they’ve recently raised is being used to fuel that project, which if successful will more than pay for itself. TC you probably understand, I’m just thinking out loud not just to disagree with you btw. I doubt they could use Veneto revenue for Olaregen at this stage, since we see Veneto comes with a full talented team, plus as we see on zip recruiting and other job sites that they’ve been hiring pharmacy personnel as they ramp up that organization.

I think we have to trust the plan and the process that Joe is implementing, especially since he personally gaurenteed nearly everything that’s taking place. For example, issues with Alpha- Joe made a gaurentee. So for him this must be a prinicipaled position that they’ve harmed the company and the shareholders, and he’s right because we can see the 13g by Alpha showing them selling a sharp amount of shares causing a regulator to peer in that slowed up the Gnbt dividend- killing momentum. But, Generex got it completed and even with the recent low volume downturn the stock is up overall from the point before the dividend. Let’s see the next roll outs of the plan, and see if momentum comes back to our advantage.

And let’s note that recently debt notes can actually be paid off per the agreement without issuing shares and regardless the warrants are priced at $3.5, if I recall correctly. No registration statement yet anyway and NO ratchet pricing which is more harmful (actually Generex had ratchet pricing for convertible notes while on Nasdaq under Anna). And Anna did that for $25 mil, on Nasdaq, worse terms, without launching a fda product. NuGenerex, no executive salaries, and launching Excellagen this quarter. Never mind Fuse, Medisource, Pantheon, Regentys, Veneto, a chain (potentially) of 13 hospitals and whatever else that’s unfolding.